Lu, Yinying

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

Xue, R., Chen, L., Zhang, C., Fujita, M., Li, R., Yan, S.-M., Ong, C. K., Liao, X., Gao, Q., Sasagawa, S., et al. (2019) · Cancer Cell

Cholangiocarcinoma and Gallbladder Cancer StudiesHepatocellular Carcinoma Treatment and Prognosis

Cited by 296

Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma

Rong, Y., Dong, Z., Hong, Z., Jin, Y., Zhang, W., Zhang, B., Mao, W., Kong, H., Wang, C., Yang, B., et al. (2017) · Experimental Cell Research

Cancer Immunotherapy and BiomarkersHepatitis B Virus Studies

Cited by 59